| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Results of Operations and Financial Condition
(Address of principal executive offices, including zip code) |
| 22 Sep 2026 |
8-K: Results of Operations and Financial Condition
Fourth quarter fiscal 2026 net revenue increased 6.4% to $16.1 million from $15.1 million in the prior-year quarter |
| 25 Jun 2026 |
8-K: Termination of a Material Definitive Agreement
On June 23, 2026, Aytu BioPharma, Inc. (the “Company”) and Lannett Company, Inc. (together with its affiliates, “Lannett”) mutually agreed to terminate, effective as of June 23, 2026, that certain exclusive license agreement entered into... |
| 13 May 2026 |
8-K: Results of Operations and Financial Condition
EXXUA -- with only a partial quarter of full sales force support -- contributed $2.4 million in net revenue supported by rapid monthly compounding script growth rates |
| 02 Apr 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +2 more
Number of Shares of Common Stock or Exchange Warrants: (the “Total Amount”) |
| 03 Feb 2026 |
8-K: Results of Operations and Financial Condition
Adjusted EBITDA1 of $(0.8) million, which includes EXXUA launch investments |
| 20 Jan 2026 |
8-K: Regulation FD Disclosure
DENVER, CO / January 20, 2026 / Aytu BioPharma, Inc. (the “Company” or “Aytu”) (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life f... |
| 10 Dec 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On December 10, 2025, Aytu BioPharma, Inc. (the “Company”) held its 2026 annual meeting of stockholders (“2026 Annual Meeting”). At the close of business on October 13, 2025, the record date for the 2026 Annual Meeting, there were 10,188... |
| 13 Nov 2025 |
8-K: Results of Operations and Financial Condition
Net income of $2.0 million, or $0.21 net income per share basic |
| 23 Sep 2025 |
8-K: Results of Operations and Financial Condition
Aytu BioPharma Reports Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results and Outlines Commercial Launch Plans for EXXUA™ |
| 07 Aug 2025 |
8-K: Termination of a Material Definitive Agreement
As previously disclosed in its United States Securities and Exchange Commission filings, Aytu BioPharma, Inc. (the “Company”) suspended its clinical development of AR101. In connection with this suspension, the Company has been engaged i... |
| 23 Jun 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
This AMENDMENT NO. 6 TO LOAN AND SECURITY AGREEMENT (this "Amendment") is dated as of June 20, 2025 (the "Amendment No. 6 Closing Date") by and among NEOS THERAPEUTICS, INC., a Delaware corporation ("Company"), NEOS THERAPEUTICS BRANDS, ... |
| 17 Jun 2025 |
8-K: Regulation FD Disclosure
In accordance with General Instruction B.2. of Form 8-K, the following information shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the ... |
| 09 Jun 2025 |
8-K: Regulation FD Disclosure; Other Events
Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA™ Opportunity and Commercialization Plan |
| 06 Jun 2025 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Introductory. Aytu BioPharma, Inc., a Delaware corporation (the “Company”), proposes to sell, pursuant to the terms of this underwriting agreement (this “Agreement”), to the several underwriters named in Schedule A hereto (the “Underwrit... |
| 06 Jun 2025 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +1 more
Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA™ (gepirone) Extended-Release Tablets in the United States |
| 21 May 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
WHEREAS, the Board of Directors (the “Board”) of Aytu BioPharma, Inc. (the “Company”) heretofore established the Aytu BioPharma, Inc. 2023 Equity Incentive Plan (the “Plan”); and |
| 14 May 2025 |
8-K: Results of Operations and Financial Condition
Net income of $4.0 million, or $0.65 and $0.21 net income per share basic and diluted, respectively |
| 12 Feb 2025 |
8-K: Results of Operations and Financial Condition
First quarterly sequential prescription increase for both ADHD and Pediatric portfolios since Q2 fiscal 2023 |
| 04 Dec 2024 |
8-K: Regulation FD Disclosure
TO: ALL CURRENT RECORD HOLDERS AND BENEFICIAL OWNERS OF COMMON STOCK OF AYTU BIOPHARMA, INC. (“AYTU” OR THE “COMPANY”) AS OF OCTOBER 9, 2024 (THE “RECORD DATE”) (“CURRENT AYTU SHAREHOLDERS”). |
Loading...